Global brokerage firm Jefferies has upgraded Zydus Lifesciences to a ‘Buy’ rating, citing the strength of the company’s US pipeline as a key driver for future growth. The brokerage raised its target price for the stock to Rs 1,450 from the previous Rs 1,210, reflecting a 30% upside potential from the previous day’s closing price … Read more
We have collated a list of recommendations from top brokerage firms from ETNow and other sources: CLSA on Delhivery: Underperform| Target Rs 488CLSA downgraded Delhivery to underperform from buy earlier post-Q4 results and slashed the target price to Rs 488 from Rs 600 earlier. The Q4 revenue growth was below expectations. Express parcel revenue declined … Read more
Indian market is likely to trade higher on Tuesday tracking positive global cues. The Nifty future closed positive with gains of 1.20% at 22393 levels on Monday. The India VIX was down by 5.65% from 13.46 to 12.70 levels. On the options front, the maximum Call OI is placed at 22,600 and then towards 22,500 … Read more
